Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

481

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
Major Depressive Disorder
Interventions
DRUG

vilazodone

titration to 40 mg tablets qd (once a day) for 8 weeks

DRUG

placebo

placebo

Trial Locations (9)

19104

University of Pennsylvania Department of Psychiatry Mood and Anxiety Disorders, Philadelphia

30328

Atlanta Institute of Medicine and Research, Atlanta

34208

Florida Clinical Research Center, Bradenton

75235

Mood Disorders Research Program and Clinic Exchange Park, Dallas

84132

University of Utah Health Sciences Ctr, Dept of Psychiatry Mood Disorders Clinic, Salt Lake City

92660

Pharmacology Research Institute, Newport Beach

97210

Summit Research Network, Portland

98004

Northwest Clinical Research Center, Bellevue

98104

Summit Research Network, Seattle

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY